Tysabri Analysis Finds No New Safety Concerns In Crohn's, RA Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec and Elan say the safety evaluation to return the multiple sclerosis therapy Tysabri to market is complete.
You may also be interested in...
Biogen Idec/Elan Resubmit Tysabri With New Risk Management Program
The multiple sclerosis therapy, which was withdrawn for safety reasons in February, could return to the market by late March 2006.
India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.
Indian Health Minister Asks Novartis to Stand Down On Gleevec Patent Fight
Indian regulators threaten compulsory licensing of the oncologic, but Novartis says it has no plans to end its bid for patent protection.